Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Drug

Zai Lab Presents ZL-1310 Clinical Results for Small Cell Lung Cancer at ASCO

Fineline Cube Jun 3, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) presented the latest results from the...

Company Drug

Alphamab Oncology Presents JSKN003 Clinical Data at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

Alphamab Oncology (HKG: 9966) presented the latest clinical data for its drug candidate JSKN003 at...

Company Drug

Innovent Biologics Presents IBI363 Clinical Results at 2025 ASCO Annual Meeting

Fineline Cube Jun 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the oral presentation of results from two clinical...

Company Drug

BeOne Medicines Wins Conditional Approval for Ziihera in HER2-Positive BTC

Fineline Cube Jun 3, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Deals

LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies

Fineline Cube Jun 3, 2025

China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million...

Company Deals

Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy

Fineline Cube Jun 3, 2025

Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced...

Company Deals

Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights

Fineline Cube Jun 3, 2025

US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...

Company Drug

MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting

Fineline Cube Jun 3, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose...

Company Deals

Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor

Fineline Cube Jun 3, 2025

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...

Company Drug

R&B Biotech Receives FDA Approval for ZS805 Gene Therapy in Fabry Disease

Fineline Cube Jun 3, 2025

Sichuan R&B Biotech, a China-based biotech firm, announced receiving clinical approval from the US Food...

Company Drug

GSK’s Linerixibat NDA Accepted by FDA for Cholestatic Pruritus in PBC Patients

Fineline Cube Jun 3, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that the New Drug Application (NDA) for...

Company Deals

Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development

Fineline Cube Jun 3, 2025

China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...

Company Drug

Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan

Fineline Cube Jun 3, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...

Company Deals

MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million

Fineline Cube Jun 3, 2025

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company

MSD Appoints Kyle Tattle as President of China Operations

Fineline Cube May 30, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...

Company Drug

Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment

Fineline Cube May 30, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received marketing approval from...

Others

MSD and Daiichi Sankyo Withdraw US Filing for Patritumab Deruxtecan in EGFR-Mutated NSCLC

Fineline Cube May 30, 2025

Partners Merck, Sharp & Dohme (MSD; NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced the...

Company Drug

Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals

Fineline Cube May 30, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...

Company Deals

CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals

Fineline Cube May 30, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...

Company Medical Device

Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA

Fineline Cube May 30, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Posts pagination

1 … 152 153 154 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.